Synthesis 2021; 53(19): 3545-3554
DOI: 10.1055/a-1509-6078
feature

Base-Free Catalytic Wittig-/Cross-Coupling Reaction Sequence as Short Synthetic Strategy for the Preparation of Highly Functionalized Arylbenzoxepinones

Linda Pudnika
a   Latvian Institute of Organic Synthesis, Aizkraukles 21, 1006 Riga, Latvia
,
Ilona Domraceva
a   Latvian Institute of Organic Synthesis, Aizkraukles 21, 1006 Riga, Latvia
,
Thomas Werner
b   Paderborn University, Department of Chemistry, Warburger Straße 100, 33098 Paderborn, Germany
c   Leibniz Institute for Catalysis, Albert-Einstein-Straße 29a, 18059 Rostock, Germany
,
Raivis Zalubovskis
a   Latvian Institute of Organic Synthesis, Aizkraukles 21, 1006 Riga, Latvia
d   Institute of Technology of Organic Chemistry, Faculty of Materials Science and Applied Chemistry, Riga Technical University, 3/7 Paula Valdena Str., 1048 Riga, Latvia
,
Aiga Grandane
a   Latvian Institute of Organic Synthesis, Aizkraukles 21, 1006 Riga, Latvia
› Author Affiliations
This work was supported by the European Regional Development Fund (ERDF, project no. 1.1.1.2/VIAA/1/16/235).


Abstract

The facile synthesis of highly functionalized building blocks with potential biological activity is of great interest to medicinal chemistry. The benzoxepinone core structures commonly exhibit biological activity. Thus, a short and efficient synthetic route towards benzoxepine containing scaffold, which enables late stage modification was developed. Namely, base-free catalytic Wittig reactions enabled the synthesis of bromobenzoxepinones from readily available starting materials. Subsequent, Suzuki–Miyaura and Stille reactions proved to be suitable methods to access a variety of benzoxepinone diaryl derivatives by late stage modification in only three steps. This three-step reaction sequence is suitable for high throughput applications and gives facile access to highly complex molecular structures, which are suitable for further functionalization. The antiproliferative properties of selected arylbenzoxepinones­ were tested in vitro on monolayer tumor cell line A549. Notably, in this initial screening, these compounds were found to be active in the micromolar range.

Supporting Information



Publication History

Received: 05 April 2021

Accepted after revision: 17 May 2021

Accepted Manuscript online:
17 May 2021

Article published online:
21 June 2021

© 2021. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany